7/103 sources · 3 publishersUpdated Oct 22, 17:19 UTC
RBC raises Elevance Health price target to $455 and keeps Sector Perform rating
RBC Capital increased its price target for Elevance Health from $424 to $455 while maintaining a Sector Perform rating. The firm also lifted its 2026 adjusted EPS guidance to at least $29.00, citing strong EPS growth and better Medicaid and ACA margins. Truist similarly raised its target to $500, keeping a Buy rating. Elevance Health is currently trading around $434.
Why it matters
RBC says the higher target reflects improved earnings outlook, which could support further upside for the stock. The new target may influence investors’ valuation models and trading decisions.
Key facts
- 1RBC raised its price target for Elevance Health from $424.00 to $455.00. marketscreener.com
- 2RBC kept a Sector Perform rating on Elevance Health. tradingview.com
- 3RBC raised its 2026 adjusted EPS guidance to at least $29.00. tradingview.com
- 4Truist raised its price target for Elevance Health from $475 to $500 and kept a Buy rating. marketscreener.com
- 5Elevance Health was trading at $434.13 at the time of the report. marketscreener.com
- 6GuruFocus reported a GF Score of 89/100 for Elevance Health. gurufocus.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.